1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Personalized Medicine and Epigenomics Market Size Growth Rate by Type: 2018 VS 2022 VS 2032
1.2.2 Reagents
1.2.3 Kits
1.2.4 Instruments
1.2.5 Enzymes
1.2.6 Services
1.3 Market by Application
1.3.1 Global Personalized Medicine and Epigenomics Market Share by Application: 2018 VS 2022 VS 2032
1.3.2 Oncology
1.3.3 Non-Oncology
1.3.4 Cancer Drug Technology
1.4 Study Objectives
1.5 Years Considered 2 Global Growth Trends
2.1 Global Personalized Medicine and Epigenomics Market Perspective (2018-2032)
2.2 Personalized Medicine and Epigenomics Growth Trends by Region
2.2.1 Personalized Medicine and Epigenomics Market Size by Region: 2018 VS 2022 VS 2032
2.2.2 Personalized Medicine and Epigenomics Historic Market Size by Region (2018-2023)
2.2.3 Personalized Medicine and Epigenomics Forecasted Market Size by Region (2023-2032)
2.3 Personalized Medicine and Epigenomics Market Dynamics
2.3.1 Personalized Medicine and Epigenomics Industry Trends
2.3.2 Personalized Medicine and Epigenomics Market Drivers
2.3.3 Personalized Medicine and Epigenomics Market Challenges
2.3.4 Personalized Medicine and Epigenomics Market Restraints 3 Competition Landscape by Key Players
3.1 Global Top Personalized Medicine and Epigenomics Players by Revenue
3.1.1 Global Top Personalized Medicine and Epigenomics Players by Revenue (2018-2023)
3.1.2 Global Personalized Medicine and Epigenomics Revenue Market Share by Players (2018-2023)
3.2 Global Personalized Medicine and Epigenomics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Personalized Medicine and Epigenomics Revenue
3.4 Global Personalized Medicine and Epigenomics Market Concentration Ratio
3.4.1 Global Personalized Medicine and Epigenomics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Personalized Medicine and Epigenomics Revenue in 2022
3.5 Personalized Medicine and Epigenomics Key Players Head office and Area Served
3.6 Key Players Personalized Medicine and Epigenomics Product Solution and Service
3.7 Date of Enter into Personalized Medicine and Epigenomics Market
3.8 Mergers & Acquisitions, Expansion Plans 4 Personalized Medicine and Epigenomics Breakdown Data by Type
4.1 Global Personalized Medicine and Epigenomics Historic Market Size by Type (2018-2023)
4.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Type (2023-2032) 5 Personalized Medicine and Epigenomics Breakdown Data by Application
5.1 Global Personalized Medicine and Epigenomics Historic Market Size by Application (2018-2023)
5.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Application (2023-2032) 6 North America
6.1 North America Personalized Medicine and Epigenomics Market Size (2018-2032)
6.2 North America Personalized Medicine and Epigenomics Market Size by Country (2018-2023)
6.3 North America Personalized Medicine and Epigenomics Market Size by Country (2023-2032)
6.4 United States
6.5 Canada 7 Europe
7.1 Europe Personalized Medicine and Epigenomics Market Size (2018-2032)
7.2 Europe Personalized Medicine and Epigenomics Market Size by Country (2018-2023)
7.3 Europe Personalized Medicine and Epigenomics Market Size by Country (2023-2032)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries 8 Asia-Pacific
8.1 Asia-Pacific Personalized Medicine and Epigenomics Market Size (2018-2032)
8.2 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Country (2018-2023)
8.3 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Country (2023-2032)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia 9 Latin America
9.1 Latin America Personalized Medicine and Epigenomics Market Size (2018-2032)
9.2 Latin America Personalized Medicine and Epigenomics Market Size by Country (2018-2023)
9.3 Latin America Personalized Medicine and Epigenomics Market Size by Country (2023-2032)
9.4 Mexico
9.5 Brazil 10 Middle East & Africa
10.1 Middle East & Africa Personalized Medicine and Epigenomics Market Size (2018-2032)
10.2 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2018-2023)
10.3 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2023-2032)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE 11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Personalized Medicine and Epigenomics Introduction
11.1.4 Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.1.5 Abbott Laboratories Recent Development
11.2 Affymetrix
11.2.1 Affymetrix Company Detail
11.2.2 Affymetrix Business Overview
11.2.3 Affymetrix Personalized Medicine and Epigenomics Introduction
11.2.4 Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.2.5 Affymetrix Recent Development
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Detail
11.3.2 Agilent Technologies Business Overview
11.3.3 Agilent Technologies Personalized Medicine and Epigenomics Introduction
11.3.4 Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.3.5 Agilent Technologies Recent Development
11.4 Astellas Pharmaceuticals
11.4.1 Astellas Pharmaceuticals Company Detail
11.4.2 Astellas Pharmaceuticals Business Overview
11.4.3 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Introduction
11.4.4 Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.4.5 Astellas Pharmaceuticals Recent Development
11.5 BAYER AG
11.5.1 BAYER AG Company Detail
11.5.2 BAYER AG Business Overview
11.5.3 BAYER AG Personalized Medicine and Epigenomics Introduction
11.5.4 BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.5.5 BAYER AG Recent Development
11.6 Bio Vision
11.6.1 Bio Vision Company Detail
11.6.2 Bio Vision Business Overview
11.6.3 Bio Vision Personalized Medicine and Epigenomics Introduction
11.6.4 Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.6.5 Bio Vision Recent Development
11.7 Celgene Corp.
11.7.1 Celgene Corp. Company Detail
11.7.2 Celgene Corp. Business Overview
11.7.3 Celgene Corp. Personalized Medicine and Epigenomics Introduction
11.7.4 Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.7.5 Celgene Corp. Recent Development
11.8 Emd Millipore
11.8.1 Emd Millipore Company Detail
11.8.2 Emd Millipore Business Overview
11.8.3 Emd Millipore Personalized Medicine and Epigenomics Introduction
11.8.4 Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.8.5 Emd Millipore Recent Development
11.9 Epigenomics AG
11.9.1 Epigenomics AG Company Detail
11.9.2 Epigenomics AG Business Overview
11.9.3 Epigenomics AG Personalized Medicine and Epigenomics Introduction
11.9.4 Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.9.5 Epigenomics AG Recent Development
11.10 Epigentex
11.10.1 Epigentex Company Detail
11.10.2 Epigentex Business Overview
11.10.3 Epigentex Personalized Medicine and Epigenomics Introduction
11.10.4 Epigentex Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.10.5 Epigentex Recent Development
11.11 Envivo Pharmaceuticals (Forum Pharmaceutricals)
11.11.1 Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Detail
11.11.2 Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview
11.11.3 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Introduction
11.11.4 Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.11.5 Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Development
11.12 Gilead Sciences
11.12.1 Gilead Sciences Company Detail
11.12.2 Gilead Sciences Business Overview
11.12.3 Gilead Sciences Personalized Medicine and Epigenomics Introduction
11.12.4 Gilead Sciences Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.12.5 Gilead Sciences Recent Development
11.13 Glaxosmithkline
11.13.1 Glaxosmithkline Company Detail
11.13.2 Glaxosmithkline Business Overview
11.13.3 Glaxosmithkline Personalized Medicine and Epigenomics Introduction
11.13.4 Glaxosmithkline Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.13.5 Glaxosmithkline Recent Development
11.14 Illumina Inc.
11.14.1 Illumina Inc. Company Detail
11.14.2 Illumina Inc. Business Overview
11.14.3 Illumina Inc. Personalized Medicine and Epigenomics Introduction
11.14.4 Illumina Inc. Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.14.5 Illumina Inc. Recent Development
11.15 Johnson & Johnson
11.15.1 Johnson & Johnson Company Detail
11.15.2 Johnson & Johnson Business Overview
11.15.3 Johnson & Johnson Personalized Medicine and Epigenomics Introduction
11.15.4 Johnson & Johnson Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.15.5 Johnson & Johnson Recent Development
11.16 Karus Therapeutics Limited
11.16.1 Karus Therapeutics Limited Company Detail
11.16.2 Karus Therapeutics Limited Business Overview
11.16.3 Karus Therapeutics Limited Personalized Medicine and Epigenomics Introduction
11.16.4 Karus Therapeutics Limited Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.16.5 Karus Therapeutics Limited Recent Development
11.17 Laboratory Corp. Of America Holdings
11.17.1 Laboratory Corp. Of America Holdings Company Detail
11.17.2 Laboratory Corp. Of America Holdings Business Overview
11.17.3 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Introduction
11.17.4 Laboratory Corp. Of America Holdings Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.17.5 Laboratory Corp. Of America Holdings Recent Development
11.18 LES Laboratoires Servier
11.18.1 LES Laboratoires Servier Company Detail
11.18.2 LES Laboratoires Servier Business Overview
11.18.3 LES Laboratoires Servier Personalized Medicine and Epigenomics Introduction
11.18.4 LES Laboratoires Servier Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.18.5 LES Laboratoires Servier Recent Development
11.19 Merck
11.19.1 Merck Company Detail
11.19.2 Merck Business Overview
11.19.3 Merck Personalized Medicine and Epigenomics Introduction
11.19.4 Merck Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.19.5 Merck Recent Development
11.20 Naturewise Biotech & Medicals Corp.
11.20.1 Naturewise Biotech & Medicals Corp. Company Detail
11.20.2 Naturewise Biotech & Medicals Corp. Business Overview
11.20.3 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Introduction
11.20.4 Naturewise Biotech & Medicals Corp. Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.20.5 Naturewise Biotech & Medicals Corp. Recent Development
11.21 Novartis Pharma AG
11.21.1 Novartis Pharma AG Company Detail
11.21.2 Novartis Pharma AG Business Overview
11.21.3 Novartis Pharma AG Personalized Medicine and Epigenomics Introduction
11.21.4 Novartis Pharma AG Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.21.5 Novartis Pharma AG Recent Development
11.22 Oncolys Biopharma Inc.
11.22.1 Oncolys Biopharma Inc. Company Detail
11.22.2 Oncolys Biopharma Inc. Business Overview
11.22.3 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Introduction
11.22.4 Oncolys Biopharma Inc. Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.22.5 Oncolys Biopharma Inc. Recent Development
11.23 Orchid Chemicals & Pharmaceuticals Limited
11.23.1 Orchid Chemicals & Pharmaceuticals Limited Company Detail
11.23.2 Orchid Chemicals & Pharmaceuticals Limited Business Overview
11.23.3 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
11.23.4 Orchid Chemicals & Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.23.5 Orchid Chemicals & Pharmaceuticals Limited Recent Development
11.24 Progen Pharmaceuticals Limited
11.24.1 Progen Pharmaceuticals Limited Company Detail
11.24.2 Progen Pharmaceuticals Limited Business Overview
11.24.3 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
11.24.4 Progen Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.24.5 Progen Pharmaceuticals Limited Recent Development
11.25 Quest Diagnostics
11.25.1 Quest Diagnostics Company Detail
11.25.2 Quest Diagnostics Business Overview
11.25.3 Quest Diagnostics Personalized Medicine and Epigenomics Introduction
11.25.4 Quest Diagnostics Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.25.5 Quest Diagnostics Recent Development
11.26 Roche Holding AG
11.26.1 Roche Holding AG Company Detail
11.26.2 Roche Holding AG Business Overview
11.26.3 Roche Holding AG Personalized Medicine and Epigenomics Introduction
11.26.4 Roche Holding AG Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.26.5 Roche Holding AG Recent Development
11.27 Rubicon Genomics
11.27.1 Rubicon Genomics Company Detail
11.27.2 Rubicon Genomics Business Overview
11.27.3 Rubicon Genomics Personalized Medicine and Epigenomics Introduction
11.27.4 Rubicon Genomics Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.27.5 Rubicon Genomics Recent Development
11.28 Takeda Pharmaceutical Company Limited
11.28.1 Takeda Pharmaceutical Company Limited Company Detail
11.28.2 Takeda Pharmaceutical Company Limited Business Overview
11.28.3 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Introduction
11.28.4 Takeda Pharmaceutical Company Limited Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.28.5 Takeda Pharmaceutical Company Limited Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
